Zynex, Inc. (NASDAQ:ZYXI) CFO Sells $71,500.00 in Stock

Zynex, Inc. (NASDAQ:ZYXI) CFO Daniel J. Moorhead sold 10,000 shares of Zynex stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $7.15, for a total transaction of $71,500.00. Following the completion of the transaction, the chief financial officer now directly owns 10,050 shares in the company, valued at $71,857.50. This trade represents a 49.88 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Zynex Stock Up 1.1 %

Shares of NASDAQ ZYXI opened at $7.35 on Friday. The company has a market cap of $234.07 million, a price-to-earnings ratio of 49.00 and a beta of 0.81. The company has a current ratio of 3.94, a quick ratio of 3.15 and a debt-to-equity ratio of 1.66. Zynex, Inc. has a 12 month low of $7.00 and a 12 month high of $13.19. The stock has a 50-day moving average price of $7.75 and a two-hundred day moving average price of $8.02.

Institutional Investors Weigh In On Zynex

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Bank of America Corp DE lifted its stake in Zynex by 6.2% in the 4th quarter. Bank of America Corp DE now owns 24,114 shares of the company’s stock valued at $193,000 after purchasing an additional 1,407 shares during the last quarter. Ameriprise Financial Inc. increased its holdings in shares of Zynex by 2.1% during the fourth quarter. Ameriprise Financial Inc. now owns 96,813 shares of the company’s stock worth $775,000 after buying an additional 1,993 shares in the last quarter. Connors Investor Services Inc. lifted its stake in shares of Zynex by 5.7% in the 4th quarter. Connors Investor Services Inc. now owns 29,858 shares of the company’s stock valued at $239,000 after acquiring an additional 1,608 shares during the last quarter. Lido Advisors LLC acquired a new stake in shares of Zynex during the 4th quarter valued at $240,000. Finally, Hancock Whitney Corp grew its position in Zynex by 44.1% during the 4th quarter. Hancock Whitney Corp now owns 40,986 shares of the company’s stock worth $328,000 after acquiring an additional 12,542 shares during the last quarter. 29.68% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $17.00 target price on shares of Zynex in a report on Friday, December 6th.

Zynex Company Profile

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.